GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
News Sanofi/Regeneron eczema data paves way for year's biggest la... Companies look to take on Pfizer after series of setbacks.
News Sanofi cholesterol drug can stay on US market - for now Sales of Praluent can continue during patent case appeal.
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
News Sanofi’s dermatitis drug dupilumab fast-tracked by FDA Drug could earn $2.8 billion if approved in AD and asthma
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.